Status:
COMPLETED
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis
Lead Sponsor:
Abu Dhabi Health Services Company
Collaborating Sponsors:
United Arab Emirates University
Cleveland Clinic Abu Dhabi
Conditions:
End-Stage Kidney Disease (ESKD)
Non-valvular Atrial Fibrillation (NVAF)
Eligibility:
All Genders
18-85 years
Brief Summary
This is a retrospective study of End-Stage Kidney Disease (ESKD) patients on dialysis receiving apixaban or warfarin at Tawam Hospital \[a tertiary care hospital in Al Ain, UAE\]. The study aims to as...
Detailed Description
Direct oral anticoagulants (DOACs), including apixaban, are used for stroke prevention in non-valvular atrial fibrillation (NVAF) and for venous thromboembolism (VTE) management. Patients with end-sta...
Eligibility Criteria
Inclusion
- Age more than 18
- CKD on dialysis for at least 1 month
- NVAF or VTE
- On Apixaban or Warfarin for at least 1 month
Exclusion
- Age less than 18
- Received dialysis for less than 1 month (i.e., were treated with dialysis for acute kidney injury).
- On Apixaban or Warfarin for less than 1 month
- Pregnancy
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 5 2024
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT06606275
Start Date
January 1 2024
End Date
November 5 2024
Last Update
November 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SEHA Tawam Hospital
Al Ain City, Abu Dhabi Emirate, United Arab Emirates